Showing 98,641 - 98,660 results of 102,951 for search '(( a web decrease ) OR ( 5 ((((mean decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.09s Refine Results
  1. 98641

    Supplementary Material for: Prediction of Therapeutic Response Using Contrast-Enhanced Ultrasound in Japanese Patients Treated with Atezolizumab and Bevacizumab for Unresectable He... by Takada H. (11871941)

    Published 2022
    “…Cases without decreased blood flow in TIC analysis (<i>n</i> = 10) had more cases with PD compared with cases with decreased blood flow (60 vs. 0%, <i>p</i> = 0.001). …”
  2. 98642

    Table_1_Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma.docx by Johanna Matull (18767917)

    Published 2024
    “…GNAQ and GNA11 mutations were common in uveal melanomas, while MAP-Kinase mutations were frequent in non-uveal melanomas with NF1, BRAF V600 and NRAS Q61 mutations occurring in decreasing frequency, consistent with a strong UV association. …”
  3. 98643

    Data_Sheet_1_Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung... by Xia Luo (169127)

    Published 2022
    “…When compared with lorlatinib and alectinib, ensartinib was associated with a lower QALY and decreased total costs; the ICERs for lorlatinib and alectinib were $934,101/ QALY and $164,888/ QALY, respectively.…”
  4. 98644
  5. 98645
  6. 98646
  7. 98647
  8. 98648
  9. 98649
  10. 98650
  11. 98651
  12. 98652
  13. 98653
  14. 98654
  15. 98655
  16. 98656
  17. 98657
  18. 98658
  19. 98659
  20. 98660